103 results on '"Loghavi, Sanam"'
Search Results
2. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
3. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia
4. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
5. Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes
6. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
7. Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma
8. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms
9. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes
10. SOHO State of the Art Updates and Next Questions—WHO Classification of Acute Myeloid Leukemia
11. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
12. Clinical Flow Cytometry Analysis in the Setting of Chronic Myeloid Neoplasms and Clonal Hematopoiesis
13. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
14. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
15. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity
16. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations
17. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
18. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
19. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation
20. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases
21. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
22. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities
23. The Implementation and Effectiveness of PathElective.com
24. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1
25. Histology of the normal ovary in premenopausal patients
26. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma
27. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience
28. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature
29. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
30. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant
31. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
32. P583: Clinical utility of optical genome mapping as an additional test to standard cytogenetic workup of hematological malignancies
33. 86. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation
34. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia
35. Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases
36. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features
37. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin
38. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes
39. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
40. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature
41. MDS-363 Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis
42. AML-727 Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia
43. Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis
44. Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia
45. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
46. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
47. Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies
48. The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
49. A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies
50. Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.